A potent GHRP that stimulates GH more powerfully than ipamorelin, with cardiac-protective properties.
Hexarelin is a synthetic hexapeptide growth hormone releasing peptide (GHRP). It is one of the most potent GHRPs developed, producing a stronger GH pulse than GHRP-2, GHRP-6, or ipamorelin. It acts on the ghrelin receptor (GHS-R1a) and potentially on a separate cardiac receptor, which may explain its observed cardioprotective effects.
Unlike ipamorelin, hexarelin does cause significant cortisol and prolactin elevation alongside GH. This limits its use in many protocols where hormonal cleanliness is desired. However, its potency and unique cardiac effects have maintained research interest.
Hexarelin has been studied for cardiovascular protection — it appears to protect cardiac tissue from ischemia and may have direct cardiac muscle effects independent of GH. This makes it potentially interesting for cardiac rehabilitation research, though it is far from clinical approval.
Research shows hexarelin produces the highest GH pulse amplitude of common GHRPs in head-to-head comparisons. Cardiac studies in animal models demonstrate protection against ischemia/reperfusion injury, reduced infarct size, and improved cardiac function. These effects appear partially independent of the GH axis.
Long-term use in humans is poorly characterized. Desensitization of GH response with continuous use has been observed — more pronounced than with ipamorelin. Cycled protocols are therefore commonly employed.
📚 Key Reference: PMID: 9024267 (hexarelin cardiac effects)
Cortisol and prolactin elevation are significant concerns compared to ipamorelin. Increased appetite. Water retention. GH-related side effects at high doses. Desensitization with prolonged continuous use. Consult your provider — hexarelin is generally considered less favorable than ipamorelin for routine GH optimization due to its less clean hormonal profile.
NOT FDA-approved. Research use only. Available through compounding pharmacies. More limited clinical use than ipamorelin due to less favorable side effect profile.